☰

Natalie A. Bezman, Ph.D. - Publications

Affiliations: 
2007 University of Pennsylvania, Philadelphia, PA, United States 
Area:
Molecular Biology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

20/38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Min-Oo G, Bezman NA, Madera S, Sun JC, Lanier LL. Proapoptotic Bim regulates antigen-specific NK cell contraction and the generation of the memory NK cell pool after cytomegalovirus infection. The Journal of Experimental Medicine. 211: 1289-96. PMID 24958849 DOI: 10.1084/Jem.20132459  0.351
2014 Robbins M, Jure-Kunkel M, Dito G, Andre P, Zhang H, Bezman N, Graziano RF. Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab Blood. 124: 4717-4717. DOI: 10.1182/BLOOD.V124.21.4717.4717  0.312
2013 Zawislak CL, Beaulieu AM, Loeb GB, Karo J, Canner D, Bezman NA, Lanier LL, Rudensky AY, Sun JC. Stage-specific regulation of natural killer cell homeostasis and response against viral infection by microRNA-155. Proceedings of the National Academy of Sciences of the United States of America. 110: 6967-72. PMID 23572582 DOI: 10.1073/Pnas.1304410110  0.399
2013 Beaulieu AM, Bezman NA, Lee JE, Matloubian M, Sun JC, Lanier LL. MicroRNA function in NK-cell biology. Immunological Reviews. 253: 40-52. PMID 23550637 DOI: 10.1111/Imr.12045  0.358
2012 Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, Best JA, Goldrath AW, Lanier LL. Molecular definition of the identity and activation of natural killer cells. Nature Immunology. 13: 1000-9. PMID 22902830 DOI: 10.1038/Ni.2395  0.402
2012 Sun JC, Madera S, Bezman NA, Beilke JN, Kaplan MH, Lanier LL. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. The Journal of Experimental Medicine. 209: 947-54. PMID 22493516 DOI: 10.1084/Jem.20111760  0.419
2011 Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the development of NK and iNKT cells. The Journal of Experimental Medicine. 208: 2717-31. PMID 22124110 DOI: 10.1084/Jem.20111386  0.341
2011 Sun JC, Beilke JN, Bezman NA, Lanier LL. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. The Journal of Experimental Medicine. 208: 357-68. PMID 21262959 DOI: 10.1084/Jem.20100479  0.393
2010 Bezman NA, Cedars E, Steiner DF, Blelloch R, Hesslein DG, Lanier LL. Distinct requirements of microRNAs in NK cell activation, survival, and function. Journal of Immunology (Baltimore, Md. : 1950). 185: 3835-46. PMID 20805417 DOI: 10.4049/Jimmunol.1000980  0.368
2010 Sonnenberg GF, Mangan PR, Bezman NA, Sekiguchi DR, Luning Prak ET, Erikson J, Maltzman JS, Jordan MS, Koretzky GA. Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody production. Blood. 115: 2186-95. PMID 20029045 DOI: 10.1182/Blood-2009-08-237438  0.598
2009 Bezman NA, Baker RG, Lenox LE, Jordan MS, Koretzky GA. Cutting edge: rescue of pre-TCR but not mature TCR signaling in mice expressing membrane-targeted SLP-76. Journal of Immunology (Baltimore, Md. : 1950). 182: 5183-7. PMID 19380761 DOI: 10.4049/Jimmunol.0802176  0.651
2008 Bezman NA, Lian L, Abrams CS, Brass LF, Kahn ML, Jordan MS, Koretzky GA. Requirements of SLP76 tyrosines in ITAM and integrin receptor signaling and in platelet function in vivo. The Journal of Experimental Medicine. 205: 1775-88. PMID 18663126 DOI: 10.1084/Jem.20080240  0.619
2007 Ménasché G, Kliche S, Bezman N, Schraven B. Regulation of T-cell antigen receptor-mediated inside-out signaling by cytosolic adapter proteins and Rap1 effector molecules. Immunological Reviews. 218: 82-91. PMID 17624945 DOI: 10.1111/J.1600-065X.2007.00543.X  0.499
2007 Bezman N, Koretzky GA. Compartmentalization of ITAM and integrin signaling by adapter molecules. Immunological Reviews. 218: 9-28. PMID 17624941 DOI: 10.1111/J.1600-065X.2007.00541.X  0.629
2007 Clemens RA, Lenox LE, Kambayashi T, Bezman N, Maltzman JS, Nichols KE, Koretzky GA. Loss of SLP-76 expression within myeloid cells confers resistance to neutrophil-mediated tissue damage while maintaining effective bacterial killing. Journal of Immunology (Baltimore, Md. : 1950). 178: 4606-14. PMID 17372019 DOI: 10.4049/Jimmunol.178.7.4606  0.695
2006 Sebzda E, Hibbard C, Sweeney S, Abtahian F, Bezman N, Clemens G, Maltzman JS, Cheng L, Liu F, Turner M, Tybulewicz V, Koretzky GA, Kahn ML. Syk and Slp-76 mutant mice reveal a cell-autonomous hematopoietic cell contribution to vascular development. Developmental Cell. 11: 349-61. PMID 16950126 DOI: 10.1016/J.Devcel.2006.07.007  0.68
2006 Abtahian F, Bezman N, Clemens R, Sebzda E, Cheng L, Shattil SJ, Kahn ML, Koretzky GA. Evidence for the requirement of ITAM domains but not SLP-76/Gads interaction for integrin signaling in hematopoietic cells. Molecular and Cellular Biology. 26: 6936-49. PMID 16943434 DOI: 10.1128/Mcb.01040-06  0.61
2006 Wu JN, Gheith S, Bezman NA, Liu QH, Fostel LV, Swanson AM, Freedman BD, Koretzky GA, Peterson EJ. Adhesion- and degranulation-promoting adapter protein is required for efficient thymocyte development and selection. Journal of Immunology (Baltimore, Md. : 1950). 176: 6681-9. PMID 16709827 DOI: 10.4049/Jimmunol.176.11.6681  0.564
2004 Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Research. 64: 8595-603. PMID 15574766 DOI: 10.1158/0008-5472.Can-04-1430  0.355
2002 Roelants FM, Torrance PD, Bezman N, Thorner J. Pkh1 and Pkh2 differentially phosphorylate and activate Ypk1 and Ykr2 and define protein kinase modules required for maintenance of cell wall integrity. Molecular Biology of the Cell. 13: 3005-28. PMID 12221112 DOI: 10.1091/Mbc.E02-04-0201  0.384
Low-probability matches (unlikely to be authored by this person)
2022 Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, et al. Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells. Haematologica. PMID 35770527 DOI: 10.3324/haematol.2021.279930  0.295
2007 Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. The Journal of Clinical Investigation. 117: 3879-89. PMID 17992257 DOI: 10.1172/Jci32614  0.292
2021 Pazina T, MacFarlane AW, Bernabei L, Dulaimi E, Kotcher R, Yam C, Bezman NA, Robbins MD, Ross EA, Campbell KS, Cohen AD. Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma. Cancers. 13. PMID 33435153 DOI: 10.3390/cancers13020226  0.279
2021 D'Souza C, Keam SP, Yeang HXA, Neeson M, Richardson K, Hsu AK, Canfield R, Bezman N, Robbins M, Quach H, Ritchie DS, Harrison SJ, Trapani JA, Prince HM, Beavis PA, et al. Myeloma NK cells are exhausted and have impaired regulation of activation. Haematologica. PMID 34011135 DOI: 10.3324/haematol.2020.277525  0.276
2019 Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma. Cancer Immunology Research. PMID 31431433 DOI: 10.1158/2326-6066.Cir-18-0579  0.274
2018 Pazina T, James AM, Jhatakia A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. Elotuzumab Promotes Self-Engagement of Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7) Between Natural Killer (NK) and Multiple Myeloma (MM) Cells to Enhance Cytotoxicity Clinical Lymphoma Myeloma and Leukemia. 18: S253-S254. DOI: 10.1016/j.clml.2018.07.156  0.265
2017 Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 6: e1339853. PMID 28932638 DOI: 10.1080/2162402X.2017.1339853  0.261
2013 Mingueneau M, Kreslavsky T, Gray D, Heng T, Cruse R, Ericson J, Bendall S, Spitzer MH, Nolan GP, Kobayashi K, von Boehmer H, Mathis D, Benoist C, Best AJ, ... ... Bezman NA, et al. The transcriptional landscape of αβ T cell differentiation. Nature Immunology. 14: 619-32. PMID 23644507 DOI: 10.1038/Ni.2590  0.256
2013 Jojic V, Shay T, Sylvia K, Zuk O, Sun X, Kang J, Regev A, Koller D, Best AJ, Knell J, Goldrath A, Joic V, Koller D, Shay T, ... ... Bezman NA, et al. Identification of transcriptional regulators in the mouse immune system. Nature Immunology. 14: 633-43. PMID 23624555 DOI: 10.1038/Ni.2587  0.249
2017 Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Advances. 1: 753-765. PMID 29296719 DOI: 10.1182/bloodadvances.2017004382  0.247
2018 Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, et al. Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Molecular Cancer Therapeutics. PMID 29654064 DOI: 10.1158/1535-7163.Mct-17-0998  0.204
2021 Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Leif Bergsagel P, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discovery. 2: 354-369. PMID 34258584 DOI: 10.1158/2643-3230.bcd-21-0038  0.201
2009 Gargiulo G, Levy S, Bucci G, Romanenghi M, Fornasari L, Beeson KY, Goldberg SM, Cesaroni M, Ballarini M, Santoro F, Bezman N, Frigè G, Gregory PD, Holmes MC, Strausberg RL, et al. NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation. Developmental Cell. 16: 466-81. PMID 19289091 DOI: 10.1016/j.devcel.2009.02.002  0.174
2020 Verkleij CPM, Jhatakia A, Broekmans MEC, Frerichs KA, Zweegman S, Mutis T, Bezman NA, van de Donk NWCJ. Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers. 12. PMID 33321969 DOI: 10.3390/cancers12123713  0.173
2021 Huang RY, Wang Y, Jhatakia AD, Deng AX, Bee C, Deshpande S, Rangan VS, Bezman N, Gudmundsson O, Chen G. Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies. Journal of the American Society For Mass Spectrometry. PMID 33415981 DOI: 10.1021/jasms.0c00399  0.13
2020 Huang RY, Wang F, Wheeler M, Wang Y, Langish R, Chau B, Dong J, Morishige W, Bezman N, Strop P, Rajpal A, Gudmundsson O, Chen G. An Integrated Approach for Characterizing Bispecific Antibody/Antigens Complexes and Mapping Binding Epitopes with SEC/MALS, Native Mass Spectrometry and Protein Footprinting. Analytical Chemistry. PMID 32639723 DOI: 10.1021/acs.analchem.0c01876  0.102
2018 Gallaher J, Larripa K, Renardy M, Shtylla B, Tania N, White D, Wood K, Zhu L, Passey C, Robbins M, Bezman N, Shelat S, Jay Cho H, Moore H. Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma. Journal of Theoretical Biology. PMID 30172689 DOI: 10.1016/J.Jtbi.2018.08.037  0.044
2023 Aghaee M, Ledzewicz U, Robbins M, Bezman N, Jay Cho H, Moore H. Determining Optimal Combination Regimens for Patients with Multiple Myeloma. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 106492. PMID 37302768 DOI: 10.1016/j.ejps.2023.106492  0.024
Hide low-probability matches.